NA
SRNE

Navellier & Associates’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Navellier & Associates’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42,767
Closed -$354K – 349
2021
Q1 		$354K Buy
42,767
+4,314
+11% +$45.6K 0.06% 219
2020
Q4 		$262K Buy
+38,453
New +$309K 0.05% 238

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Navellier & Associates's SRNE Position: Q2 2021 in Review

Navellier & Associates sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 42,767 shares — an estimated $354K sold.

Navellier & Associates first reported a position in SRNE in Q4 2020 and held it in 2 quarters. The position peaked at $354K in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Navellier & Associates reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Navellier & Associates sold 42,767 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $354K.
  • Navellier & Associates first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • Navellier & Associates's Sorrento Therapeutics, Inc. position peaked at $354K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Navellier & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.